IOncology

Dr Paz-Ares: I think this meeting is a particularly relevant meeting for continuous education, where the different and relevant aspects of lung cancer diagnosis, treatment and so on are reviewed and updated compared to standard-of-care. On top of that, some new data are typically presented. A good highlight for the current conference this year were some data updating the CHECKMATE-816 trial, showing more mature data on the benefit of chemotherapy plus nivolumab compared to chemotherapy as a neoadjuvant treatment in early stage non-small cell lung cancer. Importantly, it was suggested that an inflammatory signature may be predictive of benefit from this combination. There were some other interesting data updating the APPLE trial suggesting that third-generation TKIs like osimertinib are a better alternative compared to first-generation and then sequentially third-generation at time of progression even if using a liquid biopsy. Of course, there were updates of some other studies, including the presentation of novel phase III trials. There were two negative trials. The RESILIENT non-small cell lung cancer trial showed that the experimental drug, liposomal irinotecan, is not any better as compared to topotecan. And secondly, the CONTACT-01 trial with the addition of cabozantinib to atezolizumab does not improve prognosis, compared to standard-of-care in relapse non-small cell lung cancer.